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Background/Aim: Oedema is a common and serious side effect of thiazolidinedione 
therapy. A stratified medicines approach would aim to give thiazolidinediones to patients 
likely to have a good glycaemic response but to not develop oedema.  We investigated 
whether oedema was associated with glycaemic response to thiazolidinedione therapy. 
Methods: We retrospectively studied 11,459 patients initiating a thiazolidinedione from UK 
primary care data (Clinical Practice Research Datalink), and identified medical records of 
new oedema in the subsequent twelve months. Response was defined as change in HbA1c 
at twelve months and was adjusted for baseline HbA1c, baseline BMI, gender and 
compliance (medication possession ratio). In secondary analyses we restricted oedema 
classification to patients with concomitant weight gain. As a comparison the same analysis 
was performed in 13,089 patients initiating a sulfonylurea. 
Results: The 5% of patients with recorded oedema on thiazolidinediones had a mean (CI) 
2.2 (1.1-3.2)mmol/mol greater fall in HbA1c (p<0.001) compared to thiazolidinedione 
patients without oedema. This improved response increased when oedema was associated 
with weight gain, with a 2.5 (1.1-4)mmol/mol greater HbA1c fall when weight gain >3kg 
(<0.001) and a 3.6 (1.8-5.4)mmol/mol greater fall when weight gain >5kg (<0.001). Oedema 
was recorded in 3.7% of sulfonylurea patients and was not associated with response (HbA1c 
fall difference 1 (-0.5-2.5)mmol/mol, p=0.2), even when associated with weight gain >3kg 
(p=0.19). 
Conclusion: Patients with Type 2 diabetes who develop oedema on initiating 
thiazolidinediones have an improved glycaemic response, and more severe oedema may be 
associated with greater reductions in HbA1c. An association between oedema and 
glycaemic response was not observed in patients initiating sulfonylureas. This supports 
glycaemic lowering and fluid retention being mediated by a common pathway of 
thiazolidinedione drug action.  
 
 
